Molecular Partners (MOLN) Competitors $6.06 -0.06 (-0.98%) (As of 11/4/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrends MOLN vs. KOD, ADAP, ADVM, KPTI, HARP, CGEM, TYRA, ZYME, PLRX, and DNTHShould you be buying Molecular Partners stock or one of its competitors? The main competitors of Molecular Partners include Kodiak Sciences (KOD), Adaptimmune Therapeutics (ADAP), Adverum Biotechnologies (ADVM), Karyopharm Therapeutics (KPTI), Harpoon Therapeutics (HARP), Cullinan Therapeutics (CGEM), Tyra Biosciences (TYRA), Zymeworks (ZYME), Pliant Therapeutics (PLRX), and Dianthus Therapeutics (DNTH). These companies are all part of the "medical" sector. Molecular Partners vs. Kodiak Sciences Adaptimmune Therapeutics Adverum Biotechnologies Karyopharm Therapeutics Harpoon Therapeutics Cullinan Therapeutics Tyra Biosciences Zymeworks Pliant Therapeutics Dianthus Therapeutics Molecular Partners (NASDAQ:MOLN) and Kodiak Sciences (NASDAQ:KOD) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, risk, valuation, profitability, media sentiment, analyst recommendations, earnings, institutional ownership and dividends. Which has preferable earnings and valuation, MOLN or KOD? Molecular Partners has higher revenue and earnings than Kodiak Sciences. Molecular Partners is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMolecular Partners$6.00M37.03-$69.04M-$2.15-2.82Kodiak SciencesN/AN/A-$260.49M-$3.76-1.04 Do analysts rate MOLN or KOD? Molecular Partners presently has a consensus target price of $4.50, indicating a potential downside of 25.70%. Kodiak Sciences has a consensus target price of $5.00, indicating a potential upside of 28.21%. Given Kodiak Sciences' higher possible upside, analysts plainly believe Kodiak Sciences is more favorable than Molecular Partners.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Molecular Partners 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 3.00Kodiak Sciences 2 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.80 Which has more risk & volatility, MOLN or KOD? Molecular Partners has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500. Comparatively, Kodiak Sciences has a beta of 2.25, suggesting that its share price is 125% more volatile than the S&P 500. Does the MarketBeat Community prefer MOLN or KOD? Kodiak Sciences received 6 more outperform votes than Molecular Partners when rated by MarketBeat users. However, 46.15% of users gave Molecular Partners an outperform vote while only 27.27% of users gave Kodiak Sciences an outperform vote. CompanyUnderperformOutperformMolecular PartnersOutperform Votes1246.15% Underperform Votes1453.85% Kodiak SciencesOutperform Votes1827.27% Underperform Votes4872.73% Do insiders & institutionals have more ownership in MOLN or KOD? 26.5% of Molecular Partners shares are owned by institutional investors. Comparatively, 89.1% of Kodiak Sciences shares are owned by institutional investors. 5.9% of Molecular Partners shares are owned by company insiders. Comparatively, 45.3% of Kodiak Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is MOLN or KOD more profitable? Kodiak Sciences has a net margin of 0.00% compared to Molecular Partners' net margin of -730.27%. Molecular Partners' return on equity of -33.15% beat Kodiak Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Molecular Partners-730.27% -33.15% -29.89% Kodiak Sciences N/A -77.23%-42.44% Does the media prefer MOLN or KOD? In the previous week, Molecular Partners had 2 more articles in the media than Kodiak Sciences. MarketBeat recorded 3 mentions for Molecular Partners and 1 mentions for Kodiak Sciences. Molecular Partners' average media sentiment score of 1.00 beat Kodiak Sciences' score of 0.67 indicating that Molecular Partners is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Molecular Partners 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kodiak Sciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryMolecular Partners beats Kodiak Sciences on 10 of the 18 factors compared between the two stocks. Ad Porter & CompanyWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. Get Molecular Partners News Delivered to You Automatically Sign up to receive the latest news and ratings for MOLN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MOLN vs. The Competition Export to ExcelMetricMolecular PartnersBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$222.23M$3.11B$5.09B$8.43BDividend YieldN/A1.76%7.52%4.16%P/E Ratio-3.0616.07135.8816.71Price / Sales37.03309.871,688.5176.32Price / CashN/A144.3537.1933.56Price / Book1.123.994.614.98Net Income-$69.04M-$42.25M$116.08M$224.69M7 Day Performance-2.32%-0.22%-0.97%-0.51%1 Month Performance20.65%8.24%5.32%3.32%1 Year Performance31.09%28.29%33.75%25.51% Molecular Partners Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MOLNMolecular Partners0.8388 of 5 stars$6.06-1.0%$4.50-25.7%+31.2%$224.57M$7.84M-2.82180Positive NewsKODKodiak Sciences4.5245 of 5 stars$3.89+2.4%$5.00+28.5%+65.3%$204.69MN/A-1.0390Upcoming EarningsADAPAdaptimmune Therapeutics2.6901 of 5 stars$0.77+5.5%$3.38+341.9%+47.8%$195.82M$141.46M-2.19449ADVMAdverum Biotechnologies3.9908 of 5 stars$7.37+1.0%$28.17+282.2%-19.0%$153.30M$3.60M-0.92190News CoveragePositive NewsKPTIKaryopharm Therapeutics4.3392 of 5 stars$0.99+0.0%$5.00+405.1%+4.8%$123.43M$146.03M-0.84380HARPHarpoon Therapeutics0.7958 of 5 stars$23.01flat$23.000.0%N/A$389.61M$37.34M-2.6353CGEMCullinan Therapeutics2.1359 of 5 stars$15.83+1.8%$31.67+100.0%+60.5%$917.82M$18.94M-5.1730TYRATyra Biosciences3.7507 of 5 stars$17.07+2.3%$31.40+83.9%+20.9%$901.47MN/A-10.1020Gap UpZYMEZymeworks1.0725 of 5 stars$12.46-9.1%$17.00+36.4%+98.7%$885.28M$76.01M-8.20290Earnings ReportAnalyst ForecastNews CoveragePLRXPliant Therapeutics4.0873 of 5 stars$14.55+3.4%$40.57+178.8%-10.1%$884.64M$1.58M-4.7190DNTHDianthus Therapeutics1.4022 of 5 stars$28.59+2.6%$45.14+57.9%+135.7%$839.69M$2.83M-5.1680News Coverage Related Companies and Tools Related Companies Kodiak Sciences Competitors Adaptimmune Therapeutics Competitors Adverum Biotechnologies Competitors Karyopharm Therapeutics Competitors Harpoon Therapeutics Competitors Cullinan Therapeutics Competitors Tyra Biosciences Competitors Zymeworks Competitors Pliant Therapeutics Competitors Dianthus Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MOLN) was last updated on 11/5/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredMissed Out On Nvidia?Artificial Intelligence is a tool with the potential to create massive distributions of wealth… In fact, it...Unstoppable Prosperity | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Molecular Partners AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Molecular Partners With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
